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Objective: A task force of scientists at the International Congress on Antiphospholipid
Antibodies recognized that phosphatidylserine-dependent antiprothrombin antibodies (aPS/
PT) might contribute to a better identification of antiphospholipid syndrome (APS).
Accordingly, initial and replication retrospective, cross-sectional multicentre studies were con-
ducted to ascertain the value of aPS/PT for APS diagnosis. Methods: In the initial study (eight
centres, seven countries), clinical/laboratory data were retrospectively collected. Serum/plasma
samples were tested for IgG aPS/PT at Inova Diagnostics (Inova) using two ELISA kits. A
replication study (five centres, five countries) was carried out afterwards. Results: In the initial
study (n¼ 247), a moderate agreement between the IgG aPS/PT Inova and MBL ELISA kits
was observed (k¼ 0.598). IgG aPS/PT were more prevalent in APS patients (51%) than in
those without (9%), OR 10.8, 95% CI (4.0–29.3), p< 0.0001. Sensitivity, specificity, positive
(LRþ) and negative (LR–) likelihood ratio of IgG aPS/PT for APS diagnosis were 51%, 91%,
5.9 and 0.5, respectively. In the replication study (n¼ 214), a moderate/substantial agreement
between the IgG aPS/PT results obtained with both ELISA kits was observed (k¼ 0.630). IgG
aPS/PT were more prevalent in APS patients (47%) than in those without (12%), OR 6.4,
95% CI (2.6–16), p< 0.0001. Sensitivity, specificity, LRþ and LR– for APS diagnosis were
47%, 88%, 3.9 and 0.6, respectively. Conclusions: IgG aPS/PT detection is an easily
performed laboratory parameter that might contribute to a better and more complete identi-
fication of patients with APS. Lupus (2016) 0, 1–11.
Key words: Antiphospholipid antibodies; thrombosis; lupus anticoagulant; systemic lupus
erythematosus
Introduction
Antiphospholipid antibodies (aPL) are a heteroge-
neous group of antibodies detected in patients with
antiphospholipid syndrome (APS). The latest clas-
siﬁcation criteria for deﬁnite APS (Sydney-revised
Sapporo criteria) require the presence of at least
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one clinical manifestation and one positive labora-
tory criterion.1 Anticardiolipin antibodies (aCL),
anti-b2glycoprotein I antibodies (anti-b2GPI) and
lupus anticoagulant (LA) are the laboratory tests
included in the laboratory criteria for APS
classiﬁcation.
A number of issues concerning the deﬁnition of
aPL positive are under discussion. Current APS
classiﬁcation criteria identify a homogenous group
of APS patients, but exclude patients with clinical
manifestations highly suggestive of APS and ‘non-
criteria’ aPL, i.e. autoantibodies targeting other
plasma proteins or phospholipid-bound proteins
complexes, recognized as ‘seronegative APS’.2
In the last decade, antibodies against prothrom-
bin emerged as a potential maker for APS. The
presence of antibodies solely targeting human pro-
thrombin (aPT-A) by enzyme-linked immunosorb-
ent assay (ELISA) has been recognized since 1995.3
Antiprothrombin antibodies bind not only to pro-
thrombin coated on gamma-irradiated or activated
polyvinyl chloride ELISA plates, but also recognize
prothrombin exposed to immobilized phosphati-
dylserine, namely phosphatidylserine-dependent
antiprothrombin antibodies (aPS/PT).4–6
Although both aPT-A or aPS/PT are associated
with APS-related clinical features and can both be
present in the same patient, they belong to diﬀerent
populations of autoantibodies.5,7
Several studies have been published with regard
to the relationship between the presence of aPT-A
and APS-related clinical features with conﬂicting
conclusions.8–20 A recent systematic review sug-
gested that both antibodies against prothrombin,
aPT-A and aPS/PT, are risk factors for thrombosis,
but that aPS/PT represent a stronger risk factor for
arterial and/or venous thrombosis when compared
to aPT-A.21 In two prospective studies, the pres-
ence of aPT-A has been reported as a predictor of
thromboembolic events in patients with aPL,
mainly in those patients positive for LA.22,23
Many reports have shown the clinical utility of
aPS/PT in the diagnosis of APS.5,24–27 In a large
cohort of Japanese patients with systemic auto-
immune diseases, the presence of aPS/PT signiﬁ-
cantly correlated with LA and with the clinical
manifestations of APS.5 Furthermore, aPS/PT
appeared as the strongest independent risk factor
for obstetric complications.27 These data suggest
that aPS/PT testing might help in assessing the
risk of thrombosis and pregnancy morbidity in
patients suspected of suﬀering from APS.
An international task force of scientists analysed
critical questions related to ‘non-criteria’ aPL tests
in an evidence-based manner during the 13th
International Congress on Antiphospholipid
Antibodies. The task force members agreed that
antiprothrombin antibody assays, in particular,
aPS/PT, might potentially contribute to better rec-
ognition of APS patients.28 However, the inclusion
of antiprothrombin antibodies as one of the labora-
tory criteria of APS could not be warranted at that
time, mainly due to poor standardisation of the
aPS/PT assays. It was concluded that reproducibil-
ity of the strong correlations between aPS/PT and
APS manifestations, which were presented by some
of the investigators at the meeting, needed to be
conﬁrmed by larger collaborator studies. As a
result, a retrospective and cross-sectional multicen-
tre study was designed to evaluate the value of aPS/
PT for the diagnosis of APS. After completing the
initial study, a replication study was carried out in
order to ensure the validity of the ﬁndings.29
Patients and methods
In the initial retrospective multicentre study, poten-
tial participating centres were asked to submit data
and samples from patients with and without APS,
as well as from control participants. At each par-
ticipant institution, individuals were assigned to
one of the following groups: (1) Patients with clin-
ical APS in the presence or absence of concomitant
systemic autoimmune diseases (APS group).
Patients with clinical APS refers to patients with
events consistent with APS-associated manifest-
ations and positive for APS laboratory criteria,1
and to patients with APS-associated manifestations
for whom physicians have a strong suspicion of
APS but without APS laboratory criteria, (2)
patients without clinical APS, with and without
systemic autoimmune diseases (non-APS group),
and (3) apparently healthy individuals.
Demographics, medical history and laboratory
data from all the participants were retrospectively
collected in a questionnaire, and a serum/plasma
sample from the individuals were prepared and
stored until use.
All questionnaires were sent to the coordinating
site at Hokkaido University for the assignment of a
unique identiﬁcation code for each participant.
After receiving identiﬁcation codes, each institution
shipped the samples, with the identiﬁcation code
clearly typed on the tubes, to the analysis site at
Inova Diagnostics Inc, San Diego CA, United
States (US) (Inova).
At the analysis site, all samples were blindly
evaluated for immunoglobulin (Ig)G aPS/PT
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byELISAusing kits provided by twomanufacturers:
QUANTA LiteTM aPS/PT IgG ELISA from Inova
(US Food andDrug Administration (FDA) cleared)
and PS/PT ELISA kit for IgG isotype fromMedical
andBiologicalLaboratoriesCo.Ltd,Nagano, Japan
(MBL). Cut-oﬀs levels were set up at 30 units for
the QUANTA LiteTM aPS/PT IgG ELISA and >12
units for the MBL IgG PS/PT ELISA kit according
to the manufacturers’ instructions.
After completing the initial study in July 2013, a
replication study was performed to ensure that
results were reliable and valid.
The studies were approved by independent eth-
ical committees or institutional review boards at all
institutions involved. The studies were conducted in
accordance with the Declaration of Helsinki and
the Principles of Good Clinical Practice.
Statistical analysis
Statistical evaluation was carried out by Chi-
squared test (v2) or Fisher’s exact test, as appropri-
ate. Pearson’s correlation coeﬃcient was used for
analysing the correlations, and Cohen’s kappa test
was applied to compare the results obtained using
diﬀerent tests in the same sample. Titres of antibo-
dies were compared using Mann–Whitney U test.
Relative risk was approximated by odds ratio (OR)
and 95% conﬁdence interval (CI). Sensitivity, spe-
ciﬁcity and likelihood ratios (LRs) of aPS/PT for
the diagnosis of APS were calculated. Receiver
operating characteristic (ROC) curve analysis was
used to assess the diagnostic accuracy of the assays.
P values less than 0.05 were considered signiﬁcant.




In the initial study, 247 participants from eight cen-
tres in seven countries were included. Each site
included at least 20 individuals (Appendix 1). The
cohort comprised 199 patients and 48 apparently
healthy people. Among the patients, 126 had clin-
ical APS, of whom 77 (61%) had primary APS and
in 49 (39%), APS was diagnosed in coexistence
with other autoimmune diseases. In the group of
patients without APS (n¼ 73), 42 had systemic
autoimmune diseases and 31 had non-systemic
autoimmune diseases. Demographics and clinical
characteristics of the included population are pre-
sented in Table 1 and in Appendix 2. Seventy-ﬁve
patients (60%) had thrombotic events (with/with-
out obstetric complications), and 51 women (48%)
had obstetric manifestations without thrombotic
complications. All patients in the APS group were
reported to have positive aPL laboratory criteria
tests.
IgG aPS/PT were detected in 58% and 43% of
patients with clinical APS using the Inova and
MBL ELISA kits, respectively. Detailed data on
the prevalence of IgG aPS/PT in each of the ana-
lysed groups is shown in Appendix 3.
There was a statistically signiﬁcant correlation in
the optical density (OD) values of IgG aPS/PT
Table 1 Demographic characteristics of population
APS group Non-APS group Healthy participants All population
Initial study n¼ 126 n¼ 73 n¼ 48 n¼ 247
Sex F:M (ratio) 106:20 (5.3) 54:19 (2.8) 26:22 (1.2) 186:61 (3.0)
Mean years (range) 40.8 (20–79) 46.9 (18–77) 32.9 (23–47) 41.0 (18–79)
Race (n)a
- Caucasian 69 (55%) 37 (51%) 28 (58%) 134 (54%)
- Asian 39 (31%) 15 (21%) 20 (42%) 74 (30%)
- Hispanic – 1 (1%) – 1 (0.5%)
- Black 1 (1%) 1 (1%) – 2 (1%)
Replication study n¼ 96 n¼ 67 n¼ 51 n¼ 214
Sex F:M (ratio) 85:11 (7.7) 52:15 (3.5) 46:5 (9.2) 183:31 (5.9)
Mean years (range) 41.1 (14–74) 44.7 (25–88) 36.5 (21–60) 41.1 (14–88)
Race (n)b
- Caucasian 70 (73%) 47 (70%) 41(80%) 158 (74%)
- Asian 23 (24%) 19 (28%) 8 (16%) 50 (23%)
- Hispanic 1 (1%) 1 (1%) 1 (2%) 3 (1%)
- Black – – 1 (2%) 1 (0.5%)
n: number; F: female, M: male; APS: antiphospholipid syndrome.
aIn 35 individuals information was not provided. bIn three individuals information was not provided.
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obtained with both ELISA kits (Pearson’s correl-
ation coeﬃcient: r¼ 0.827, p< 0.001) (Figure 1(a)).
A moderate agreement between the IgG aPS/PT
Inova and MBL ELISA kits was observed
(k¼ 0.598).
Concordant IgG aPS/PT results were con-
sidered when the sample gave a positive or nega-
tive result in both ELISA kits. A total of 204
samples displayed concordant IgG aPS/PT results
and were subsequently analysed. Forty-three sam-
ples (17%) displayed discrepant IgG aPS/PT
results between the Inova and MBL ELISA kits
(Appendix 4).
Among the 204 samples with concordant results,
99 were obtained from patients with clinical APS,
58 from non-APS patients and 47 from healthy
individuals. Positive titres of IgG aPS/PT were
more prevalent in patients with clinical APS
(51%) than in those without (9%), OR 10.8, 95%
CI (4.0-29.3), p< 0.0001. Sensitivity, speciﬁcity,
positive LR (LRþ) and negative LR (LR–) of
IgG aPS/PT for the diagnosis of APS were 51%,
91%, 5.9 and 0.5, respectively. The diagnostic
accuracy of IgG aPS/PT for the diagnosis of
APS, the thrombotic manifestations, and the preg-
nancy complications was assessed by ROC curves,
and the area under the curve (AUC) values are pre-
sented in Table 2.
Titres of IgG aPS/PT detected by either Inova or
MBL ELISA assays were signiﬁcantly higher in
patients with clinical APS than in those without
(p< 0.001), or in healthy controls (p< 0.001)
(Figure 2(a)).
The presence of IgG aPS/PT signiﬁcantly cor-
related with a history of thrombosis, OR 11.0,
Figure 1 Correlation of IgG aPS/PT results obtained with commercial ELISAs, Inova and MBL, in samples from the initial and
replication cohorts. (a) Correlation of the IgG aPS/PT optical density (OD) values between Inova and MBL ELISA kits in samples
from the initial study. There was a statistically significant correlation in the IgG aPS/PT OD values obtained with both ELISAs
(Pearson’s correlation coefficient: r¼ 0.827, p< 0.001). (b) Correlation of the IgG aPS/PT OD values between Inova and MBL
ELISA kits in samples from the replication study. A statistically significant correlation in the IgG aPS/PT OD values obtained with
both ELISAs was observed (Pearson’s correlation coefficient: r¼ 0.803, p< 0.001).
IgG aPS/PT: positive titres of phosphatidylserine-dependent antiprothrombin antibodies in Inova and MBL assays; ELISA:
enzyme-linked immunosorbent assay; MBL: Medical and Biological Laboratories Co.
Table 2 Diagnostic value of IgG aPS/PT for antiphospholi-
pid syndrome
Inova AUC (95%CI) MBL AUC (95%CI)
Initial study
APS diagnosis 0.780 (0.716–0.844)a 0.769 (0.704–0.834)a
Thrombosis 0.719 (0.649–0.795)a 0.691 (0.612–0.770)a
Pregnancy complications 0.664 (0.563–0.766)b 0.721 (0.625–0.816)a
Replication study
APS diagnosis 0.753 (0.679–0.827)a 0.770 (0.700–0.840)a
Thrombosis 0.808 (0.731–0.885)a 0.850 (0.789–0.910)a
Pregnancy complications 0.595 (0.483–0.706)c 0.549 (0.436–0.662)c
IgG: immunoglobulin G; aPS/PT: phosphatidylserine-dependent anti-
prothrombin antibodies; AUC: area under the curve calculated using
receiver operating characteristic curve; CI: confidence intervals; MBL:
Medical and Biological Laboratories Co.
ap< 0.001. bp¼ 0.002. cNot statistically significant.
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95% CI (3.8–31.3), both arterial and venous
thrombosis OR 8.1, 95% CI (2.5–26.0), and OR
12.7, 95% CI (4.1–40.0), respectively, all
p< 0.001. In addition, IgG aPS/PT was more
frequently found in patients with a history of
obstetric APS, OR 10.6, 95% CI (3.5–32.1),
p< 0.001 (Table 3).
Table 4 shows the aPL proﬁles of the analysed
participants. In this cohort, IgG/M aCL, IgG/M
anti-b2GPI and LA were frequently found in
patients with clinical APS, with a prevalence of
68%, 55% and 90%, respectively. We evaluated
the association between aPL criteria and APS
manifestations. LA, but not IgG/M aCL nor IgG/
IgM anti-b2GPI, was signiﬁcantly correlated with a
history of thrombosis. On the other hand, IgG/M
aCL, IgG/IgM anti-b2GPI and LA signiﬁcantly
correlated with a history of pregnancy complications
(data not shown).
Replication study
In order to validate the performance of IgG aPS/
PT, we recruited a new sample set of 214 individ-
uals from ﬁve new centres in ﬁve countries. Each
individual site included at least 40 participants
(Appendix 1). The new cohort comprised 163
patients and 51 apparently healthy people.
Among the patients, the diagnoses were as follows:
clinical APS (n¼ 96), systemic autoimmune disease
without APS (n¼ 45), and non-systemic
autoimmune disease (n¼ 22). Among patients
with clinical APS, 55 (57%) had primary APS
manifestations and in 41 patients (43%), APS was
Figure 2 Distribution of IgG aPS/PT titres in samples from the initial and replication cohorts. Distribution of IgG aPS/PT titres
in 204 samples with concordant results in the initial study ((a) and (b)) and 180 samples in the replication study ((c) and (d)). Titres
of IgG aPS/PT detected by either Inova ((a), (c)) or MBL ((b), (d)) ELISA kits were significantly higher in patients with clinical
antiphospholipid syndrome (APS) than in those without APS (non-APS), or in healthy controls. Data are shown as individual
results. The dashed line indicates the cut-offs for positivity that were set up at 30 units (Inova) and >12 units (MBL).
IgG aPS/PT: positive titres of phosphatidylserine-dependent antiprothrombin antibodies in Inova and MBL assays; ELISA:
enzyme-linked immunosorbent assay; MBL: Medical and Biological Laboratories Co.
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diagnosed concomitant with other systemic auto-
immune diseases. Fifty-eight patients (60%) had
thrombotic APS (with/without obstetric complica-
tions), and 37 women had obstetric APS in the
absence of thrombotic complications. Seventeen
patients had APS-associated manifestations with-
out APS laboratory criteria. Nine patients had
obstetric events, ﬁve patients had thrombotic
events, and in three patients thrombotic and preg-
nancy complications were reported. The demo-
graphic characteristics of the population included
in the replication study were similar to those of the
initial study (Table 1, Appendix 2).
There was a statistically signiﬁcant correlation
among the OD values of IgG aPS/PT obtained
with both ELISA kits (Pearson’s correlation coeﬃ-
cient: r¼ 0.803, p< 0.001) (Figure 1(b)). A substan-
tial agreement between the IgG aPS/PT Inova and
MBL ELISA kits was observed (k¼ 0.630).
IgG aPS/PT were detected in 55% and 41% of
patients with clinical APS using Inova and MBL
ELISA kits, respectively. The detailed data of
Table 4 Profile of antiphospholipid antibodies
APS group Non-APS group Healthy individuals v2a pa
Sample positive/ Sample tested (%)
Initial study (n¼ 99) (n¼ 58) (n¼ 47)
aCL IgG 58/99 (59) 19/58 (33) 0/37 (0) 9.8 0.003
aCL IgM 23/81 (28) 11/58 (19) 0/37 (0) 1.6 NS
aCL IgG/M 65/95 (68) 27/58 (47) 0/37 (0) 7.2 0.01
Anti b2GPI IgG 31/67 (46) 5/37 (14) 0/32 (0) 11.3 0.001
Anti b2GPI IgM 14/66 (21) 6/36 (17) 0/29 (0) 0.3 NS
Anti b2GPI IgG/M 36/66 (55) 11/36 (31) 0/28 (0) 5.4 0.023
Lupus anticoagulant 80/89 (90) 11/41 (27) 0/38 (0) 53.1 <0.001
aPS/PT IgG 50/99 (51) 5/58 (9) 1/47 (2) 28.2 <0.001
Replication study (n¼ 76) (n¼ 57) (n¼ 49)
aCL IgG 36/69 (60) 5/57 (9) 1/49 (2) 26.8 <0.001
aCL IgM 19/63 (30) 2/55 (4) 0/48 (0) 14.1 <0.001
aCL IgG/M 42/68 (62) 5/56 (9) 1/49 (2) 36.4 <0.001
Anti b2GPI IgG 34/65 (52) 4/56 (7) 0/47 (0) 28.5 <0.001
Anti b2GPI IgM 14/48 (29) 3/43 (7) 1/41 (2) 7.4 0.007
Anti b2GPI IgG/M 37/62 (60) 6/45 (13) 1/41 (2) 23.3 <0.001
Lupus anticoagulant 37/70 (53) 6/56 (11) 0/48 (0) 24.6 <0.001
aPS/PT IgG 36/76 (47) 7/57 (12) 0/49 (0) 18.3 <0.001
aCL: anticardiolipin antibodies; anti-b2GPI: anti-b2-glycoprotein I antibodies; IgG/M: immunoglobulin (Ig)G and/or IgM isotype; APS: antipho-
spholipid syndrome; aPS/PT: phosphatidylserine dependent antiprothrombin antibodies.
aAPS patients vs. non-APS patients. p¼Fisher exact test; NS: not statistically significant.
Table 3 IgG aPS/PT and clinical manifestations of antiphospholipid syndrome









n (%) OR 95% (CI)* p valueb
APS group 99 50 (51) 76 50 (47)
Thrombosis 59 30 (51) 11.0
(3.8–31.3)
< 0.001 49 30 (61) 11.3
(4.2–30.0)
< 0.001
Arterial 30 13 (43) 8.1
(3.5–26.0)
< 0.001 22 14 (64) 12.5
(3.9–40.5)
< 0.001
Venous 33 18 (55) 12.7
(4.1–40.0)
< 0.001 25 16 (64) 12.7
(4.1–40.0)
< 0.001
Pregnancy complications 40 20 (50) 10.6
(3.5–32.1)
< 0.001 27 6 (22) 2.0
(0.6–6.8)
NS
Non-APS group 58 5 (9) 57 7 (12)
IgG: immunoglobulin G; APS: antiphospholipid syndrome; IgG aPS/PT: positive titres of IgG phosphatidylserine-dependent antiprothrombin
antibodies in Inova and MBL assays; OR: odds ratio; CI: confidence interval; MBL: Medical and Biological Laboratories Co.
aAPS vs non APS. bp¼Fisher exact test. NS: not statistically significant.
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prevalence of IgG aPS/PT in each of the analysed
groups is shown in Appendix 3. IgG aPS/PT were
detected as the only aPL in one out of 17 patients
(6%) with clinical APS without APS laboratory
criteria.
A total of 182 samples (85%) displayed concord-
ant IgG aPS/PT results and were subsequently ana-
lysed. Discrepant results (15%) are shown in
Appendix 4. Among 182 samples with concordant
results, 76 were obtained from patients with clinical
APS, 57 from non-APS patients and 49 from
healthy individuals. IgG aPS/PT were more preva-
lently found to be positive in patients with clinical
APS (47%) than in those without (12%), OR 6.4,
95% CI (2.6–16.0), p< 0.0001. Sensitivity, speciﬁ-
city, LRþ and LR– of IgG aPS/PT for the diagno-
sis of APS were 47%, 88%, 3.9 and 0.6,
respectively.
Titres of IgG aPS/PT detected by either Inova or
MBL ELISA assays were signiﬁcantly higher in
patients with clinical APS than in those without
APS (p< 0.001 and p¼ 0.001, respectively), or in
healthy controls (both p< 0.001).
The accuracy of IgG aPS/PT for the diagnosis of
APS, as well as for the history of thrombotic and
the obstetric manifestations, were assessed by ROC
curves and AUC values (Table 2).
The presence of IgG aPS/PT signiﬁcantly corre-
lated with thrombotic events, both arterial and
venous (OR 11.3, 95% CI (4.2–30.0), p< 0.001)
(Table 3). Conversely, IgG aPS/PT were not
found more prevalent in women with pregnancy
complications than in those without.
The aPL proﬁle in the replication cohort is
shown in Table 4. IgG/M aCL, IgG/IgM anti-
b2GPI and LA signiﬁcantly correlated with a his-
tory of thrombosis, but did not correlate with a
history of pregnancy complications (data not
shown).
Discussion
This multicentre study represents a collaborative
eﬀort to assess the value of IgG aPS/PT testing
for the diagnosis of APS. The known existence of
patients with clinical manifestations suggestive of
APS in the absence of aCL, anti-b2GPI or LA
has propelled the search for additional diagnostic
tests that could contribute to a better identiﬁcation
of APS patients. Negative results using only the
available criteria aPL tests for APS evaluation
could be related to the inadequate performance of
these assays, but also to the presence of
autoantibodies with diﬀerent antigenic speciﬁcities.
Several studies have reported the presence of aPS/
PT in patients with APS, usually in association with
other aPL.30,31 LA correlated with IgG aPS/PT and
predicted thrombosis in APS.5,27,31 However, the
clinical relevance of aPS/PT determination in the
routine evaluation of patients with suspicion of
APS remains to be fully elucidated.
Results from this multicentre study conﬁrmed
the high prevalence of IgG aPS/PT in patients
with clinical APS in two independent cohorts.
Our ﬁndings are in concordance with previous
reports showing that aPS/PT are autoantibodies
frequently found in APS patients.21,26 Our study
evaluated the signiﬁcance of IgG aPS/PT for the
diagnosis of APS in a heterogeneous population
of individuals with diﬀerent clinical backgrounds.
There are several assays currently used for aPS/PT
testing. To avoid the variability in the aPS/PT
results related either to the type of assay or to the
assays’ performance characteristics, all samples
were blindly tested using two diﬀerent IgG aPS/
PT ELISA kits. All samples from the initial study
were tested at the same time, and the same meth-
odology was applied later in the replications study.
Previous works have reported the relationship
between aPS/PT and arterial and venous throm-
bosis.21,32 Some studies support the association of
aPS/PT with arterial thrombosis, mainly in the set-
ting of cerebrovascular events.33 Others reports
showed the correlation between aPS/PT and
venous thrombosis.27,31 In our study, in both
cohorts arterial and venous thromboses were asso-
ciated with IgG aPS/PT.
Antibodies to aPS/PT have also been related to
pregnancy loss.5,7,34 We observed an association
between IgG aPS/PT and pregnancy complications
in the initial study; however, the replication study
failed to conﬁrm such an association. The reason
for this discrepancy might be related to the hetero-
geneity of patients collected at the several centres
involved in this multicentre study, or might be due
to the diversity in the deﬁnition of pregnancy com-
plications. In the initial study, a history of obstetric
complications was reported in 45% of women.
Most of these women fulﬁlled APS obstetric criteria
and were included in the APS group. In contrast, in
the replication study, despite the fact that a history
of obstetric complications was reported in 38% of
females, some of these complications did not fulﬁl
the APS obstetric criteria. Our study comprised a
variety of patients with diﬀerent obstetric compli-
cations reﬂecting the real population managed by
clinicians at each site. Considering that we failed
to ﬁnd an association between aCL, anti-b2GPI,
aPS/PT multicentre study for APS diagnosis
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LA and a history of obstetric complications in the
replication cohort, aPS/PT would have behaved in
a similar fashion.
Several clinical studies have demonstrated that
the presence of LA activity is the most signiﬁcant
risk factor for thrombotic events.35–37 In this study,
LA was frequently found in patients with APS
manifestations (90% and 53%, initial and replica-
tion study, respectively). The elevated percentage of
LA in the initial study might be related to the het-
erogeneity in LA detection, reﬂecting the variation
of the LA results among the laboratories. The pres-
ence of IgG aPS/PT was signiﬁcantly associated
with the positivity of LA, in both the initial and
replication study, in agreement with previous pub-
lications (data not shown).5,27,31,38 The association
between aPS/PT and LA suggested that aPS/PT
might be of help to conﬁrm the presence of LA activ-
ity and useful in the evaluation of APS. aPS/PT have
been reported in patients with thrombotic events in
the absence of antibodies to cardiolipin or b2GPI.39
Hoxha et al.40 found aPS/PT in 9.4% of patients
with clinical features suggestive of APS but negative
for the three aPL criteria tests. In the present study,
all APS patients from the initial cohort have APS
laboratory criteria, precluding evaluation of the
potential ‘added value’ of aPS/PT testing to the diag-
nosis of APS. In the replication cohort, in patients
with clinical APS without positive aPL criteria tests
(n¼ 17), IgG aPS/PT were detected in one patient
(6%) with thrombosis and pregnancy complications.
Our ﬁndings are in agreement with previous observa-
tions suggesting that, in case of APS suspicion and
absence of criterial aPL, testing for aPS/PT might
contribute to support the APS diagnosis.
An excellent agreement between the Inova and
MBL IgG aPS/PT assays has been already
reported.41 We further showed moderate to sub-
stantial agreements between IgG aPS/PT results
obtained with the two ELISAs, suggesting that
comparable results can be obtained using these
two commercial kits.
In our study, IgG aPS/PT showed a high speci-
ﬁcity for APS (91% and 88% in the initial and
replication cohorts, respectively). Moreover,
higher titres of IgG aPS/PT were found in people
with suspicion of or deﬁnite APS than in the other
groups of individuals.
This study conﬁrms, in two large cohorts of
participants assembled from multiple institutions,
previous observations indicating that IgG aPS/PT
are associated with APS, despite the fact that they
are not yet included in the APS laboratory criteria
for APS classiﬁcation. Testing for IgG aPS/PT
could be useful for identifying patients at risk of
developing APS.26
This study has some limitations. Samples were
deﬁned based on clinical and laboratory grounds.
The deﬁnition of APS was based on clinicians’
judgement. The diﬀerent criteria used for the inclu-
sion of patients in the APS group might inﬂuence
the study ﬁndings. The number of patients included
in the subgroup analysis is lower than what was
expected. However, the sample sizes in both
cohorts are large enough to indicate that IgG
aPS/PT are frequently found in APS patients, and
that their detection might contribute to a better
identiﬁcation of APS patients. Additional large
prospective studies are needed to deﬁne the speciﬁc
contribution of aPS/PT as a potential marker for
APS diagnosis. Another limitation is the retrospect-
ive design of the study. Demographic, clinical and
laboratory data were obtained from the medical
records at each participant centre and some infor-
mation was not available. Furthermore, results
from laboratory investigation at each participant
centre were referred using diﬀerent units, range,
and cut-oﬀs precluding the speciﬁc analysis.
In conclusion, this international multicentre study
using two diﬀerent acceptable ELISA kits has shown
that IgG aPS/PTare autoantibodies frequently found
in patients with APS, playing a role as an additional
marker ofAPS for clinical researchers, presumably as
well as for clinical practice.Measurement of IgG aPS/
PT, in conjunction with aCL, anti-b2GPI and LA,
might contribute to a better and more complete iden-
tiﬁcation of patients at risk of thrombotic complica-
tions. IgG aPS/PT should be considered as potential
additional laboratory criterion forAPS classiﬁcation.
Prospective clinical studies will clarify the risk of
developing thrombosis and/or pregnancy morbidity
related to classical aPL and/or IgG aPS/PT in the
population at risk.
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Appendix 1




Centres participating in the initial study
Hokkaido University Hospital, Sapporo, Japan 45
Favaloro University, Buenos Aires, Argentina 23
Nagoya City University Hospital, Nagoya, Japan 30
Fernando Fonseca Hospital, Lisbon, Portugal 38
University Medical Centre Ljubljana,
Ljubljana, Slovenia
29
Hospital Universitario Cruces, Bizkaia, Spain 30
King’s College, London, UK 20




Centres participating in the replication study
University of Milan, Milan, Italy 41
National Center for Child Health and Development,
Tokyo, Japan
48
Jagiellonian University, Cracow, Poland 41
Hospital Clı´nic, University of Barcelona, Barcelona,
Catalonia, Spain
41
University of Utah and ARUP Laboratories,







APS group 126 (51%) 96 (45%)
Primary APS 77 (61%) 55 (57%)
APS and systemic autoimmune diseases 49 (39%) 41 (43%)
SLE 49 (100%) 39 (95%)
Systemic sclerosis – 1 (2%)
Raynaud – 1 (2%)
Thrombotic APS 75 (60%) 59 (61%)
Obstetric APS 51 (40%) 37 (39%)
Non-APS group 73 (30%) 67 (31%)
Systemic autoimmune disease 42 (58%) 45 (67%)
SLE 18 (43%) 32 (71%)
RA 7 (17%) 2 (4%)
Vasculitis 5 (12%) 2 (4%)
Systemic sclerosis 5 (12%) 2 (4%)
Primary Sjo¨gren’s 3 (7%) 4 (9%)
Ankylosing spondylitis 2 (5%) –
Psoriatic spondylitis 1 (2%) –
Sharp syndrome 1 (2%) –
Dermatomyositis – 1 (2%)
Polymyalgia rheumatica – 1 (2%)
Mixed connective tissue disease – 1 (2%)
Other diseases 31 (42%) 22 (33%)
Renal disease 9 (29%) –
Arterial hypertension 4 (13%) 6 (27%)
Osteoarthritis 4 (13%) 2 (9%)
Asthma 3 (10%) –
Facial erythema 2 (6%) –
Bipolar disorders 2 (6%) –
Infection 1 (3%) 3 (14%)
(continued)
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Gout 1 (3%) 1 (5%)
Others 5 (16%)a 10 (45%)b
Healthy participants 48 (19%) 51 (24%)
APS: antiphospholipid syndrome; SLE: systemic lupus erythematosus;
RA: rheumatoid arthritis; n¼ number of participants.
aOthers include: diabetes mellitus (n¼ 1), preeclampsia (n¼ 1), breast
cancer (n¼ 1), speech problem (n¼ 1), one episode of idiopathic throm-
bocytopenic purpura (n¼ 1). bOthers include: pain syndrome (n¼ 1),
schizophrenia (n¼ 1), cellulitis (n¼ 1), carpal tunnel syndrome (n¼ 1),
migraine (n¼ 1), atrial fibrillation (n¼ 1), celiac disease (n¼ 1), adrenal























Inova n (%) 20 (74) 23 (48) 18 (82) 12 (41) 73 (58) 6 (14) 5 (16) 11 (15) 2 (4)



















Inova n (%) 24 (83) 15 (50) 5 (42) 9 (36) 53 (55) 13 (29) 3 (14) 16 (24) 0 (0)
MBL n (%) 19 (66) 12 (40) 5 (42) 3 (12) 39 (41) 7 (16) 1 (5) 8 (12) 2 (4)
IgG aPS/PT: positive titres of IgG phosphatidylserine-dependent antiprothrombin antibodies in Inova and MBL assays; APS: antiphospholipid
syndrome; n¼number of participants; AD: autoimmune disease setting; P: antiphospholipid syndrome-associated manifestations in absence of
concomitant autoimmune disease; MBL: Medical and Biological Laboratories Co.





















All population (n¼ 247) 204 (83) 56 (23) 148 (60) 43 (17 ) 30 (12) 13 (5)
APS group (n¼ 126) 99 (79) 50 (40) 49 (39) 27 (21) 23 (18) 4 (3)
Non-APS group (n¼ 73) 58 (79) 5 (7) 53 (73) 15 (21) 6 (8) 9 (12)
Healthy subjects (n¼ 48) 47 (98) 1 (2) 46 (96) 1 (2 ) 1 (2) 0 (0)
Replication study
All population (n¼ 214) 182 (85) 42 (20) 140 (65) 32 (15 ) 26 (12) 6 (3)
APS group (n¼ 96) 76 (79) 35 (36) 41 (43) 20 (21) 17 (18) 3 (3)
Non-APS group (n¼ 67) 57 (85) 7 (11) 50 (75) 10 (15) 9 (13) 1 (1)
Healthy participants (n¼ 51) 49 (96) 0 (0) 49 (96) 2 (4 ) 0 (0) 2 (4)
IgG aPS/PT: positive titres of IgG phosphatidylserine-dependent antiprothrombin antibodies in Inova and MBL assays; APS: antiphospholipid
syndrome; MBL: Medical and Biological Laboratories Co.; ELISA: enzyme-linked immunosorbent assay. Cut-offs: Inova IgG aPS/PT 30 units,
MBL IgG aPS/PT> 12 units.
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